Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

Marie Kostine, Thierry Schaeverbeke, Marine Gross‐Goupil et al.|European Journal of Cancer|2021

Cited by 93